share_log

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

forte biosciences成功获得5300万美元的超额认购定向增发,以推进FB102在自身免疫病领域的临床项目,预计在2025年将发布关键数据。
Benzinga ·  2024/11/20 09:05

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

forte biosciences在超额认购的定向增发中获得5300万美元,以推进FB102在自身免疫疾病领域的临床项目,预计将于2025年发布关键数据。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发